BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21342358)

  • 1. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
    Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
    Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
    J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
    Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
    Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of glucocorticoids in Kawasaki disease.
    Miura M
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S; Kimura M; Ishikawa T; Ohzeki T
    Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
    Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
    Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
    Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
    Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
    Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
    Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
    Yoshikane Y; Okuma Y; Miyamoto T; Hashimoto J; Fukazawa R; Kato T; Takeda A; Suda K; Matsushita T; Hiroe M; Imanaka-Yoshida K
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):82. PubMed ID: 34090475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ; Jung JW
    Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
    Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
    Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease - A Multicenter Retrospective Study.
    Okuma Y; Suda K; Nakaoka H; Katsube Y; Mitani Y; Yoshikane Y; Ichida F; Matsushita T; Shichino H; Shiraishi I; Abe J; Hiroe M; Yoshida T; Imanaka-Yoshida K
    Circ J; 2016 Oct; 80(11):2376-2381. PubMed ID: 27746411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
    Ebata R; Yasukawa K; Nagai K; Saito Y; Higashi K; Homma J; Takada N; Takechi F; Saito N; Kobayashi H; Okunushi K; Hamada H; Kohno Y; Hanaoka H; Shimojo N
    Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.